I often see this work well for individuals who are already doing many of the right thingseating well, moving their bodies, working on sleep and stressbut still feel weight-loss resistant. This slower, gentler dosing strategy can be a good fit for people with a history of GI issues like IBS or chronic constipation or who tend to be sensitive to medications in general
If future research confirms these findings, it could help explain why some patients respond differently to different GLP-1 medications
Moreover, semaglutide is evolving past just diabetes and weight loss, thus expanding into treatments for heart failure, chronic kidney disease, and metabolic dysfunction
Dementia: Obesity is whats known as a pro-inflammatory disease: It can lead to chronic inflammation throughout the body
These dual targeting strategies of glucagon receptors offer exciting opportunities for treating obesity, diabetes, and even Alzheimers, where appetite and metabolic dysfunction play critical roles